Pycnidione, a fungus-derived agent, induces cell cycle arrest and apoptosis in A549 human lung cancer cells

Chemico-Biological Interactions

Volumn 197, Issue 1, 2012, Pages 23-30

  Hsiao, Che Jen ^a   Hsiao, Shih Hsin ^b   Chen, Wei Lin ^c   Guh, Jih Hwa ^d   Hsiao, George ^c   Chan, Yen Ju ^c   Lee, Tzong Huei ^c   Chung, Chi Li ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Cell cycle arrest; Fungus; Lung cancer; Pycnidione; Theissenia rogersii

Indexed keywords

CASPASE 3; CASPASE 8; CYCLIN D1; CYCLIN E; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYCNIDIONE; REACTIVE OXYGEN METABOLITE; SURVIVIN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG ISOLATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; FUNGUS; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; THEISSENIA ROGERSII;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; FUNGI; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN SPECIES; TROPOLONE;

FUNGI;

EID: 84859187737     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2012.03.004     Document Type: Article

References (66)

1. P. Pittayakhajonwut, M. Theerasilp, P. Kongsaeree, A. Rungrod, M. Tanticharoen, Y. Thebtaranonth, Pughiinin A, a sesquiterpene from the fungus Kionochaeta pughii BCC 3878, Planta Med. 68 (2002) 1017-1019. (Pubitemid 35448997)
2. A.D. Wright, N. Lang-Unnasch, Potential antimalarial lead structures from fungi of marine origin, Planta Med. 71 (2005) 964-966. (Pubitemid 41658577)
3. J.E. Baldwin, A.V. Mayweg, K. Neumann, G.J. Pritchard, Studies toward the biomimetic synthesis of tropolone natural products via a hetero Diels-Alder reaction, Org. Lett. 1 (1999) 1933-1935.
4. F. Mayerl, Q. Gao, S. Huang, S.E. Klohr, J.A. Matson, D.R. Gustavson, D.M. Pirnik, R.L. Berry, C. Fairchild, W.C. Rose, Eupenifeldin, a novel cytotoxic bistropolone from Eupenicillium brefeldianum, J. Antibiot. (Tokyo) 46 (1993) 1082-1088. (Pubitemid 23254149)
5. G.H. Harris, K. Hoogsteen, K.C. Silverman, S.L. Raghoobar, G.F. Bills, R.B. Lingham, J.L. Smith, H.W. Dougherty, C. Cascalesa, F. Peláeza, Isolation and structure determination of pycnidione, a novel bistropolone stromelysin inhibitor from a Phoma sp, Tetrahedron 49 (1993) 2139-2144.
6. M. Lim, D.M. Jablons, Matrix metalloproteinase expression in lung cancer, Methods Mol. Med. 74 (2003) 349-356.
7. 1 phase arrest through p53-dependent pathway in human lung adenocarcinoma A549 cells, and in vivo tumor growth suppression, Bioorg. Med. Chem. Lett. 20 (2010) 6508-6512.
8. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M.J. Thun, Cancer statistics, 2008, CA Cancer J. Clin. 58 (2008) 71-96. (Pubitemid 351521864)
9. P. Karna, S.M. Sharp, C. Yates, S. Prakash, R. Aneja, EM011 activates a survivindependent apoptotic program in human non-small cell lung cancer cells, Mol. Cancer 8 (2009) 93.
10. J.Y. Wu, C.J. Yu, J.Y. Shih, C.H. Yang, P.C. Yang, Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer, Lung cancer 67 (2010) 348-354.
11. C. St Germain, N. Niknejad, L. Ma, K. Garbuio, T. Hai, J. Dimitroulakos, Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3, Neoplasia 12 (2010) 527-538.
12. S. Ramalingam, C.P. Belani, Paclitaxel for non-small cell lung cancer, Expert Opin. Pharmacother. 5 (2004) 1771-1780. (Pubitemid 39117720)
13. H. Zhu, C. Smith, C. Ansah, N.J. Gooderham, Responses of genes involved in cell cycle control to diverse DNA damaging chemicals in human lung adenocarcinoma A549 cells, Cancer Cell Int. 5 (2005) 28.
14. M.A. Castro, G. Schwartsmann, J.C. Moreira, Intercellular contact-dependent survival of human A549, NCI-H596 and NCI-H520 non-small cell lung carcinoma cell lines, Braz. J. Med. Biol. Res. 34 (2001) 1007-1013. (Pubitemid 33614038)
15. M. Di Maio, C. Gridelli, C. Gallo, F. Shepherd, F.V. Piantedosi, S. Cigolari, L. Manzione, A. Illiano, S. Barbera, S.F. Robbiati, L. Frontini, E. Piazza, G.P. Ianniello, E. Veltri, F. Castiglione, F. Rosetti, V. Gebbia, L. Seymour, P. Chiodini, F. Perrone, Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials, Lancet Oncol. 6 (2005) 669-677. (Pubitemid 41222757)
16. Y. Xu, N. Jiang, H. Yu, Effect of glutathione combined with cisplatin and oxaliplatin on the proliferation and apoptosis of lung carcinoma cell line, Toxicol. Mech. Methods 20 (2010) 487-492.
17. C.H. Bosken, Q. Wei, C.I. Amos, M.R. Spitz, An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer, J. Natl. Cancer Inst. 94 (2002) 1091-1099. (Pubitemid 34830729)
18. G.M. Cragg, D.J. Newman, Plants as a source of anti-cancer agents, J. Ethnopharmacol. 100 (2005) 72-79. (Pubitemid 41073525)
19. Y.H. Cheah, H.L. Azimahtol, N.R. Abdullah, Xanthorrhizol exhibits antiproliferative activity on MCF-7 breast cancer cells via apoptosis induction, Anticancer Res. 26 (2006) 4527-4534. (Pubitemid 46031527)
20. D.C. Altieri, Validating survivin as a cancer therapeutic target, Nat. Rev. Cancer 3 (2003) 46-54. (Pubitemid 37328886)
21. W.Y. Choi, B.T. Choi, W.H. Lee, Y.H. Choi, Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells, Biomed. Pharmacother. 62 (2008) 637-644.
22. C. Fleury, B. Mignotte, J.L. Vayssiere, Mitochondrial reactive oxygen species in cell death signaling, Biochimie 84 (2002) 131-141. (Pubitemid 34946949)
23. H. Ha, E.Y. Oh, H.B. Lee, The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases, Nat. Rev. Nephrol. 5 (2009) 203-211.
24. M.K. Durand, J.S. Bodker, A. Christensen, D.M. Dupont, M. Hansen, J.K. Jensen, S. Kjelgaard, L. Mathiasen, K.E. Pedersen, S. Skeldal, T. Wind, P.A. Andreasen, Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis, Thromb. Haemostasis 91 (2004) 438-449. (Pubitemid 38396865)
25. S.F. Yang, S.C. Chu, S.J. Liu, Y.C. Chen, Y.Z. Chang, Y.S. Hsieh, Antimetastatic activities of Selaginella tamariscina (Beauv.) on lung cancer cells in vitro and in vivo, J. Ethnopharmacol. 110 (2007) 483-489. (Pubitemid 46386361)
26. Y.W. Shih, Y.C. Lee, P.F. Wu, Y.B. Lee, T.A. Chiang, Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase-2 and urokinase-plasminogen activator, Hepatol. Res. 39 (2009) 998-1009.
27. S. Ulisse, E. Baldini, S. Sorrenti, M. D'Armiento, The urokinase plasminogen activator system: a target for anti-cancer therapy, Curr. Cancer Drug Targets 9 (2009) 32-71.
28. Y.M. Ju, H.M. Hsieh, M.C. Ho, D.H. Szu, M.J. Fang, Theissenia rogersii sp. nov. and phylogenetic position of Theissenia, Mycologia 99 (2007) 612-621.
29. C.J. Hsiao, T.K. Li, Y.L. Chan, L.W. Hsin, C.H. Liao, C.H. Lee, P.C. Lyu, J.H. Guh, WRC-213, an L-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance. identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers, Biochem. Pharmacol. 75 (2008) 847-856.
30. Y.W. Sun, W.J. Huang, C.J. Hsiao, Y.C. Chen, P.H. Lu, J.H. Guh, Methoxychalcone induces cell-cycle arrest and apoptosis in human hormone-resistant prostate cancer cells through PI 3-kinase-independent inhibition of mTOR pathways, Prostate 70 (2010) 1295-1306.
31. C.J. Hsiao, Y.F. Ho, J.T. Hsu, W.L. Chang, Y.C. Chen, Y.C. Shen, P.C. Lyu, J.H. Guh, Mana-Hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress, Naunyn-Schmiedeberg's Arch. Pharmacol. 378 (2008) 599-608.
32. B.M. Ryan, N. O'Donovan, M.J. Duffy, Survivin: a new target for anti-cancer therapy, Cancer Treat. Rev. 35 (2009) 553-562.
33. Y.T. Su, H.L. Chang, S.K. Shyue, S.L. Hsu, Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway, Biochem. Pharmacol. 70 (2005) 229-241.
34. H.U. Simon, A. Haj-Yehia, F. Levi-Schaffer, Role of reactive oxygen species (ROS) in apoptosis induction, Apoptosis 5 (2000) 415-418. (Pubitemid 32162623)
35. J. Zhao, Plant troponoids: chemistry, biological activity, and biosynthesis, Curr. Med. Chem. 14 (2007) 2597-2621. (Pubitemid 350018473)
36. 1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function, Cancer Lett. 286 (2009) 240-249.
37. E. Bremer, G. van Dam, B.J. Kroesen, L. de Leij, W. Helfrich, Targeted induction of apoptosis for cancer therapy: current progress and prospects, Trends Mol. Med. 12 (2006) 382-393. (Pubitemid 44164637)
38. A. Sakaue-Sawano, T. Kobayashi, K. Ohtawa, A. Miyawaki, Drug-induced cell cycle modulation leading to cell-cycle arrest, nuclear mis-segregation, or endoreplication, BMC Cell Biol. 12 (2011) 2.
39. H.L. Oh, D.K. Lee, H. Lim, C.H. Lee, HY253, a novel decahydrofluorene analog, from Aralia continentalis, induces cell cycle arrest at the G1 phase and cytochrome c-mediated apoptosis in human lung cancer A549 cells, J. Ethnopharmacol. 129 (2010) 135-139.
40. C.C. Cheng, S.M. Yang, C.Y. Huang, J.C. Chen, W.M. Chang, S.L. Hsu, Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells, Cancer Chemother. Pharmacol. 55 (2005) 531-540.
41. S.H. Chang, J.H. Bae, D.P. Hong, K.D. Choi, S.C. Kim, E. Her, S.H. Kim, C.D. Kang, Dryopteris crassirhizoma has anti-cancer effects through both extrinsic and intrinsic apoptotic pathways and G0/G1 phase arrest in human prostate cancer cells, J. Ethnopharmacol. 130 (2010) 248-254.
42. H. Oyaizu, Y. Adachi, S. Taketani, R. Tokunaga, S. Fukuhara, S. Ikehara, A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis, Mol. Cell Biol. Res. Commun. 2 (1999) 36-41. (Pubitemid 129536946)
43. Y.Y. Chan, C.S. Chang, L.H. Chien, T.F. Wu, Apoptotic effects of a high performance liquid chromatography (HPLC) fraction of Antrodia camphorata mycelia are mediated by down-regulation of the expressions of four tumor-related genes in human non-small cell lung carcinoma A549 cell, J. Ethnopharmacol. 127 (2010) 652-661.
44. D.Y. Shin, H.J. Shin, G.Y. Kim, J. Cheong, I.W. Choi, S.K. Kim, S.K. Moon, H.S. Kang, Y.H. Choi, Streptochlorin isolated from Streptomyces sp. induces apoptosis in human hepatocarcinoma cells through a reactive oxygen species-mediated mitochondrial pathway, J. Microbiol. Biotechnol. 18 (2008) 1862-1868.
45. L. Kren, J. Brazdil, M. Hermanova, V.N. Goncharuk, B.V. Kallakury, P. Kaur, J.S. Ross, Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases, Appl. Immunohistochem. Mol. Morphol. 12 (2004) 44-49. (Pubitemid 38332319)
46. J.I. Chao, H.F. Liu, The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells, Mol. Pharmacol. 69 (2006) 154-164.
47. B.M. Ryan, G.E. Konecny, S. Kahlert, H.J. Wang, M. Untch, G. Meng, M.D. Pegram, K.C. Podratz, J. Crown, D.J. Slamon, M.J. Duffy, Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1, Annu. Oncol. 17 (2006) 597-604.
48. J. Wang, Y. Jin, Z. Xu, Z. Zheng, S. Wan, Involvement of caspase-3 activity and survivin downregulation in cinobufocini-induced apoptosis in A 549 cells, Exp. Biol. Med. (Maywood) 234 (2009) 566-572.
49. Y.S. Kim, H.O. Jin, S.K. Seo, S.H. Woo, T.B. Choe, S. An, S.I. Hong, S.J. Lee, K.H. Lee, I.C. Park, Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression, Biochem. Pharmacol. 82 (2011) 216-226.
50. S.L. Shankar, S. Mani, K.N. O'Guin, E.R. Kandimalla, S. Agrawal, B. Shafit-Zagardo, Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways, J. Neurochem. 79 (2001) 426-436. (Pubitemid 32988959)
51. A.T. Lau, Y. Wang, J.F. Chiu, Reactive oxygen species: current knowledge and applications in cancer research and therapeutic, J. Cell. Biochem. 104 (2008) 657-667. (Pubitemid 351671652)
52. T. Ozben, Oxidative stress and apoptosis: impact on cancer therapy, J. Pharm. Sci. 96 (2007) 2181-2196. (Pubitemid 47477879)
53. S. Prasad, J. Ravindran, B. Sung, M.K. Pandey, B.B. Aggarwal, Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins, Mol. Cancer Ther. 9 (2010) 856-868.
54. J. Moungjaroen, U. Nimmannit, P.S. Callery, L. Wang, N. Azad, V. Lipipun, P. Chanvorachote, Y. Rojanasakul, Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation, J. Pharmacol. Exp. Ther. 319 (2006) 1062-1069.
55. R.J. Kelly, A. Lopez-Chavez, D. Citrin, J.E. Janik, J.C. Morris, Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin, Mol. Cancer 10 (2011) 35.
56. T. Nakahara, K. Yamanaka, S. Hatakeyama, A. Kita, M. Takeuchi, I. Kinoyama, A. Matsuhisa, K. Nakano, T. Shishido, H. Koutoku, M. Sasamata, YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model, Anticancer Drugs 22 (2011) 454-462.
57. X.Q. Chen, S. Yang, Z.Y. Li, H.S. Lu, M.Q. Kang, T.Y. Lin, Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells, Mol. Med. Rep. 5 (2012) 917-922.
58. R.M. Terek, G.K. Schwartz, K. Devaney, L. Glantz, S. Mak, J.H. Healey, A.P. Albino, Chemotherapy and P-glycoprotein expression in chondrosarcoma, J. Orthop. Res. 16 (1998) 585-590. (Pubitemid 28512438)
59. Y. Ogawa, T. Takahashi, T. Kobayashi, M. Toda, A. Nishioka, S. Kariya, H. Seguchi, H. Yamamoto, S. Yoshida, Comparison of radiation-induced reactive oxygen species formation in adult articular chondrocytes and that in human peripheral T cells: possible implication in radiosensitivity, Int. J. Mol. Med. 11 (2003) 455-459.
60. A.K. Maiti, Genetic determinants of oxidative stress-mediated sensitization of drug-resistant cancer cells, Int. J. Cancer 130 (2012) 1-9.
61. Y.H. Kang, E. Lee, M.K. Choi, J.L. Ku, S.H. Kim, Y.G. Park, S.J. Lim, Role of reactive oxygen species in the induction of apoptosis by alpha-tocopheryl succinate, Int. J. Cancer 112 (2004) 385-392. (Pubitemid 39390601)
62. H. Pedersen, J. Grondahl-Hansen, D. Francis, K. Osterlind, H.H. Hansen, K. Dano, N. Brunner, Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma, Cancer Res. 54 (1994) 120-123. (Pubitemid 24042098)
63. U.A. Lademann, M.U. Romer, Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1), Thromb. Haemostasis 100 (2008) 1041-1046.
64. D.J. Schneider, Y. Chen, B.E. Sobel, The effect of plasminogen activator inhibitor type 1 on apoptosis, Thromb. Haemostasis 100 (2008) 1037-1040.
65. R.M. Wanner, P. Spielmann, D.M. Stroka, G. Camenisch, I. Camenisch, A. Scheid, D.R. Houck, C. Bauer, M. Gassmann, R.H. Wenger, Epolones induce erythropoietin expression via hypoxia-inducible factor-1 alpha activation, Blood 96 (2000) 1558-1565. (Pubitemid 30658491)
66. M. Pennati, M. Folini, N. Zaffaroni, Targeting survivin in cancer therapy: fulfilled promises and open questions, Carcinogenesis 28 (2007) 1133-1139. (Pubitemid 47062670)